中国原研抗肿瘤新药物的临床试验  

The clinical trials of China innovative new anti-cancer drugs

作　　者：石远凯 孙燕 Shi Yuankai;Sun Yan(Department of Medical Oncology,Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院内科抗肿瘤分子靶向药物临床研究北京市重点实验室,100021

出　　处：《中华肿瘤杂志》2019年第1期68-72,共5页Chinese Journal of Oncology

摘　　要：随着政策扶持、新药研发能力提高和经济社会发展,中国临床试验平台建设不断加强和完善,中国抗肿瘤新药临床试验在过去几十年中取得了长足的发展,多个国产原研抗肿瘤新药相继上市,为中国患者提供了更多的治疗选择。本文对近年来中国原研抗肿瘤新药的试验研究进行回顾,重点介绍原研抗肿瘤新药临床试验取得的成果。With the support of the national policies, the improvement of research ability and the development of economy and society, China clinical trials have developed rapidly. Many achievements are made in the clinical trials of new anti-cancer drugs during last several decades. Many innovative new drugs have come into the market and gained influence at home and abroad. Those drugs provide more treatment options for Chinese patients. This article reviews the results of new anti-tumor drug clinical trials, with special focus on the challenge and chance for the new anti-cancer drug clinical trials in China.

关 键 词：肿瘤 继发原发性 药物治疗 

分 类 号：R969.4[医药卫生—药理学]